How Do You Spell BCR ABL PROTO ONCOGENES?

Pronunciation: [bˌiːsˌiːˈɑːɹ ˈabə͡l pɹˈə͡ʊtə͡ʊ ˈɒnkə͡ʊd͡ʒˌiːnz] (IPA)

The term "bcr abl Proto Oncogenes" is often spelled out phonetically as "bee-see-are ay-bee-ell proh-toh ahn-kuh-jeenz." The letters "bcr abl" refer to specific genes that have been found to be involved in the development of certain types of cancer. The "Proto Oncogenes" are a group of genes that, if mutated, can lead to the development of cancerous cells. Understanding the spelling of these terms is essential for healthcare professionals who diagnose and treat patients with cancer.

Meaning and Definition
Common Misspellings
Basic Check Advanced Check

BCR ABL PROTO ONCOGENES Meaning and Definition

  1. BCR-ABL proto-oncogenes, also known as the Philadelphia chromosome, refers to a specific genetic rearrangement found in certain types of cancer cells, particularly in chronic myelogenous leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). It is a fusion gene created by the translocation of genetic material between chromosomes 9 and 22, resulting in the abnormal formation of a fusion protein called BCR-ABL.

    The BCR-ABL fusion gene is the consequence of a chromosomal abnormality known as the Philadelphia chromosome, which occurs when a piece of chromosome 9 and a piece of chromosome 22 break off and switch places during cell division. As a result, the ABL proto-oncogene from chromosome 9 is fused with the BCR (breakpoint cluster region) gene from chromosome 22.

    This genetic fusion leads to the production of the BCR-ABL fusion protein, which has constitutive tyrosine kinase activity. Tyrosine kinase is an enzyme that plays a crucial role in regulating cell growth and division. When BCR-ABL is activated, it continuously stimulates cell proliferation and inhibits apoptosis, leading to uncontrolled growth and division of cancer cells.

    The presence of BCR-ABL proto-oncogenes in cancer cells has important clinical implications as it serves as a therapeutic target. Targeted drugs, such as tyrosine kinase inhibitors (TKIs), specifically inhibit BCR-ABL activity and have revolutionized the treatment of CML and certain forms of ALL. These drugs have significantly improved patient outcomes and survival rates, transforming CML from a fatal disease to a chronic manageable condition.

Common Misspellings for BCR ABL PROTO ONCOGENES

  • vcr abl proto oncogenes
  • ncr abl proto oncogenes
  • hcr abl proto oncogenes
  • gcr abl proto oncogenes
  • bxr abl proto oncogenes
  • bvr abl proto oncogenes
  • bfr abl proto oncogenes
  • bdr abl proto oncogenes
  • bce abl proto oncogenes
  • bcd abl proto oncogenes
  • bcf abl proto oncogenes
  • bct abl proto oncogenes
  • bc5 abl proto oncogenes
  • bc4 abl proto oncogenes
  • bcr zbl proto oncogenes
  • bcr sbl proto oncogenes
  • bcr wbl proto oncogenes
  • bcr qbl proto oncogenes
  • bcr avl proto oncogenes
  • bcr anl proto oncogenes